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Vandenbulcke (University of Leuven and University Hospitals Leuven, Leuven, Belgium); Verheijen et al., 4 Thessaloniki, Thessaloniki, Greece), Alberto Lleó, Juan Fortea, Rafael Blesa (Department of 1 Neurology, Memory Unit, Hospital de Sant Pau, Barcelona, Spain). Verheijen et al., 6 1. Introduction 1 TANK-binding kinase 1 (TBK1) is a serine/threonine-protein kinase involved in autophagy 2 and inflammatory response (Weidberg and Elazar, 2011) . TBK1 interacts with the optineurin 3 (OPTN) protein and with multiple interferon regulatory factors (IRFs), mediating NF-kappa-4 B (NFκB) activity (Cirulli, et al., 2015 ,Clement, et al., 2008 ,Larabi, et al., 2013 . Recently,

5
TBK1 has been demonstrated to regulate mitosis and microtubule stability via the TBK1-6 CEP170 complex (Pillai, et al., 2015) . Cirulli, et al., 2015 ,Freischmidt, et al., 2015 ,Gijselinck, et al., 2015 . In addition, several 11 missense variants have been reported to lead to loss of function, e.g. by inhibiting TBK1 12 interaction with OPTN (Freischmidt, et al., 2015 ,Pottier, et al., 2015 . Recently, missense (van der Zee, et al., 2017) . However, given the range of 16 functions and substrates of TBK1 and the current absence of insight in the pathomechanism 17 linking TBK1 LoF to FTD/ALS, causal inferences should be made with caution.
18
Episodic memory loss and disorientation in time and/or space appear to be frequent early 19 symptoms in carriers of a pathogenic TBK1 LoF mutation (Van Mossevelde, et al., 2015) , 20 even resulting in a clinical diagnosis of Alzheimer's disease (AD) in some carriers (Pottier, et 21 al., 2015 ,Van Mossevelde, et al., 2015 . This has led to the recommendation to consider and AD (Van Mossevelde, et al., 2015) . Verheijen et al., 7 Here, we report a massive parallel resequencing of TBK1 in a large European cohort The cohort under study consisted of 1253 EOAD patients originating from Flanders-Belgium
Germany (n=91), and Czech Republic (n=11), and 2117 age-matched European control 9 individuals originating from Flanders-Belgium (n=1042), Spain (n=334), Portugal (n=124),
10
Italy (n=340) and Sweden (n=277) ( Table 1) . A detailed description of cohort procedures and 11 characteristics is provided in (Verheijen, et al., 2016) . In the patient cohort, average onset age 12 was 58.9 ± 6.2 years. Information on familial history of AD was present for 756/1253 (60%) PSEN1, PSEN2, ABCA7, C9orf72, MAPT, PRNP and GRN were 16 excluded from the cohort (Cruts, et al., 2012 ,Cuyvers, et al., 2015a (Cuyvers, et al., 2015) .
17
Average age at inclusion for the control cohort was 67.5 ± 10.0 years. Percentage women was 18 59% for both the patient and the control cohort. RNA derived from lymphoblast cells using an Illumina HiSeq2000 sequencer as previously 20 described (Verheijen, et al., 2016) . A detailed description of sequencing procedures can be 21 found in the supplementary information. Verheijen et al., 9 Low frequency (MAF between 0.01 and 0.05) and common (MAF ≥ 0.05) variants located in 1 the TBK1 coding region were tested for deviations from Hardy-Weinberg Equilibrium using 2 PLINK (Purcell, et al., 2007 based on cohort size. Fixed-effects meta-analysis was performed using the R package rmeta.
Statistical analysis
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Nominal p-values were corrected for the number of variants tested using Bonferroni 11 correction.
12
The effect of rare TBK1 variants (MAF < 0.01) on AD risk was assessed using an aggregation determined according to (Gijselinck, et al., 2015) and correspond to NCBI reference 20 sequence NP_037386.1. Differences in TBK1 expression were calculated using an unpaired 21 non-parametric (Mann-Whitney) test. 
In-vitro NFκB activity
24
The effect of mutant TBK1 on NFκB activity in the IFN pathway was investigated by in vitro The effect of the identified rare variants on NFκB induction was assessed in vitro by a 21 luciferase reporter assay (Figure 2 ). This included 14 TBK1 variants, i.e. the in-frame deletion Verheijen et al., 13 to the predicted most deleterious variants (CADD PHRED score >20), we observed nominal Verheijen et al., 14 database (pLI = 1) (Lek, et al., 2016 (Pottier, et al., 2015 ,Van Mossevelde, et al., 2015 . Although carriers of mutations 
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Verheijen et al., 15 1 We did not observe an enrichment of rare variants in EOAD patients compared to controls 2 (carrier frequency of 1.4% in both), in line with previous association studies performed on 3 FTD and ALS patients (Freischmidt, et al., 2015) . Rare variants exclusively observed in 4 patients were not more often novel and/or predicted to be pathogenic (based on CADD score) domain is required for TBK1 kinase activity and trans-phosphorylation activity in vitro (Shu, 13 et al., 2013) . In absence of a positive family history, we were unable to further investigate the functionality, argues against a significant role of rare TBK1 variants in EOAD.
23
No associations of TBK1 common and low frequency variants with dementia spectrum 24 disorder diagnoses have yet been reported. In our meta-analysis covering EOAD cohorts M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT Verheijen et al., 16 originating from 5 European countries, a common synonymous variant (rs7486100) showed 1 association in a recessive model. In light of the hypothesis that loss of TBK1 can contribute 2 to neurodegeneration, we tested the effect of the risk allele on TBK1 expression.
3
Interestingly, RNA sequence analysis on lymphoblast cell lines of homozygous carriers of the 4 risk-increasing allele rs7486100-T showed decreased TBK1 expression. In line with this,
5
carriers of the rs7486100-T allele showed decreased expression of TBK1 in multiple tissues 6 according to the Gtex database, with lowest expression levels in homozygous rs7486100-T 7 carriers. This variant tags a ~150 kb region of strong linkage disequilibrium extending to the 8 flanking genes, and there is no evidence supporting a direct regulatory effect of rs7486100 9 (RegulomeDB score 6), warranting further investigation of common eQTLs in the region and 10 their association with neurodegeneration spectrum disorders. Of note, however, rs7486100
11
did not show association with late-onset AD in a meta-analysis of genome-wide association 12 studies (Lambert, et al., 2013) .
13
In conclusion, this investigation of common and rare variants in TBK1 in a large European initial clinical diagnosis of AD (Pottier, et al., 2015 ,Van Mossevelde, et al., 2015 .
2
Missense mutations leading to significant reduction of NFκB activation were detected in AD 3 patients, but despite the fact that these mutations may act as risk alleles in FTD (van der Zee, 4 et al., 2017) they were not significantly enriched in EOAD patients compared to controls.
5
While our findings do not support a role for TBK1 in the pathogenesis of EOAD, the 6 recurring ambiguity of clinical diagnosis in carriers of pathogenic TBK1 mutations 7 necessitates further research on the clinical presentation of TBK1 carriers. Verheijen et al., 20 Figure legends Acknowledgements:
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The authors thank the personnel of the Genomic Service Facility and of the Bioinformatics • Rare coding variants in the FTD/ALS gene TBK1 are not enriched in EOAD
• We report a TBK1 LoF mutation in a patient with clinical AD
• Atypical course or family history of FTD/ALS may point to a TBK1 LoF mutation in AD
• A common TBK1 SNP associated with reduced TBK1 expression may increase risk of EOAD
